Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease

We investigated the usefulness of cerebrospinal fluid (CSF) beta-amyloid42 (Abeta42), beta-amyloid40 (Abeta40) and tau analyses in the diagnosis of Alzheimer's disease (AD). The study included 41 definite AD cases, 80 patients with probable AD. 27 with other dementias and 39 neurological controls. Abeta42, Abeta340 and tau protein concentrations in CSF were measured of using ELISA assays. Abeta42 levels were decreased and tau increased in AD. Combination of Abeta42 and tau resulted a sensitivity of 50.4% for AD and specificities of 94.8% for controls and 85.2% for other dementias. Ninety-one percent of the patients with Abeta42 below the cutoff value (340 pg/ml) and tau above the cutoff value (380 pg/ml) had AD. AD patients carrying apoE epsilon4 allele had lower Abeta42 (P < 0.005) and higher tau (P < 0.05) levels than those without an E4 allele, and 18 (81.8%) of the 22 AD patients who had normal Abeta42 and tau levels were apoE e4 allele non-carriers. Low Abeta42 and high tau concentration in CSF strongly support the diagnosis of AD. Measurement of Abeta42 may help the early diagnosis of cases at risk for AD such as apoE E4 allele carriers.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  L. Wahlund,et al.  Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ϵ4 during 14 months follow-up , 1996, Neuroscience Letters.

[3]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[4]  H. Soininen,et al.  Alzheimer pathology of patients carrying apoliprotein E ϵ4 allele , 1995, Neurobiology of Aging.

[5]  H. Soininen,et al.  CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease , 1998, Neurology.

[6]  S. Hirai,et al.  Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease , 1998, Journal of the Neurological Sciences.

[7]  B. Dastugue,et al.  [Apolipoprotein E and Alzheimer's disease]. , 1998, Annales de biologie clinique.

[8]  A. Kurz,et al.  Cerebrospinal protein tau is elevated in early Alzheimer's disease , 1996, Neuroscience Letters.

[9]  H. Wiśniewski,et al.  Increased plasma amyloid β protein 1–42 levels in Down syndrome , 1998, Neuroscience Letters.

[10]  T. Raffin,et al.  Genetic testing and Alzheimer disease: Has the time come? , 1998, Nature Medicine.

[11]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[12]  J. Trojanowski,et al.  Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.

[13]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[14]  S. Hirai,et al.  Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease , 1997, Journal of the Neurological Sciences.

[15]  J. Trojanowski,et al.  Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease. , 1999, Journal of Alzheimer's disease : JAD.

[16]  T. Sunderland,et al.  Apolipoprotein E ϵ4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease , 1998, International journal of geriatric psychiatry.

[17]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[18]  Jan Six,et al.  Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay , 1993 .

[19]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[20]  C. Hock,et al.  Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease , 1997, Neuroscience Letters.

[21]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[22]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[23]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[24]  D. Galasko,et al.  Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease , 1997, Neurology.

[25]  L. Schad,et al.  Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging , 1997, Molecular Psychiatry.

[26]  S. Hirai,et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan , 1998 .

[27]  J. Growdon,et al.  Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype , 1995, Annals of neurology.

[28]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[29]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[30]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[31]  R. Wolfert,et al.  Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease , 1995 .

[32]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.